The United Kingdom and the United States have concluded a major bilateral deal that will keep no import taxes on British medicine products going into the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to raise funding on medicines through the NHS. This commitment ensures that duties on these vital exports will be held at zero for a timeframe of the next three years.
This agreement comes after earlier statements to dramatically increase import taxes on branded pharmaceutical products, with figures discussed reaching one hundred percent.
"This deal with the United Kingdom strengthens the worldwide climate for innovative medicines and introduces much-needed fairness to American-British medicine commerce," a release noted.
Trade Impact
Pharmaceuticals represent one of the Britain's biggest export categories to the United States, which is easily the largest destination for major UK drugmakers.
Trade data show that in the one-year period prior to September, the UK exported pharmaceutical products valued at billions to the US. This value made up 17.4% of total UK exports in that timeframe.
"This deal secures work, boosts capital expenditure and facilitates the UK to emerge as a international leader for life sciences," a government official commented.
Detailed UK Commitments
The deal entails several key changes from the British government:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a goal to increase total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to stay within budget will be limited at 15%. Last year, repayments topped twenty percent.
Broader Context
This agreement follows a long-running dispute between the drug companies and the British authorities over medicine costs and regulatory access.
These tensions were intensified by claims that US patients were paying significantly more for the same drugs than people in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or abandoned, while major funding commitments have been directed toward American operations.
The Science Minister acknowledged that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had decreased as a share of its resources over the previous ten-year period.
